Proactive Investors - Run By Investors For Investors

MaxCyte pre-clinical data shows correction of sickle cell disease mutation

Pre-clinical data presented Friday (May 18) at an industry assessed the use of non-viral CRISPR-mediated gene-correction in the treatment of the blood disorder
MaxCyte pre-clinical data shows correction of sickle cell disease mutation
Sickle cell is a blood disorder

MaxCyte Inc's (LON:MXCT) technology may have a role to play in the treatment of sickle cell disease (SCD).

Pre-clinical data presented Friday (May 18) at an industry assessed the use of  non-viral CRISPR-mediated gene-correction in the treatment of the blood disorder.

The data from work with the National Institutes of Health's National Heart Lung and Blood Institute demonstrated the potential of MaxCyte's technologies and the non-viral CRISPR gene correction in the treatment of SCD.

READ: The abstract here 

Delegates at the American Society of Gene and Cell Therapy, held in Chicago, were provided the information in a poster.

The company's chief executive, Doug Doerfler, said: "We're encouraged that MaxCyte's technology is at the forefront of enabling non-viral  CRISPR-mediated correction of disease mutations at clinically-relevant levels.

"We're excited by these results for their potential to bring therapeutic benefit to individuals living with SCD."

 

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018
Article
October 10 2018

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use